Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (08) : 799-805     DOI: 10.3971/j.issn.1000-8578.2022.21.1532
|
A New N-staging System for Predicting Postoperative Survival of M0 Stage Inflammatory Breast Cancer
SUI Daxing1, WANG Xueying2, ZHANG Jiaxin2
1. Graduate School, Dalian Medical University, Dalian 116000, China; 2. Department of Thyroid and Breast Surgery, Subei Peoplp’s Hospital, Yangzhou 225000, China
Download: PDF(6079 KB)   ( 33 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Objective To establish a new N-stage system combining the number of metastatic lymph nodes and the ratio of metastatic lymph nodes for postoperative M0 stage inflammatory breast cancer patients. Methods Based on the data of inflammatory breast cancer patients in the SEER database, the number of metastatic lymph nodes and the ratio of metastatic lymph nodes were calculated. A new N-staging system was established and compared with the 8th edition of AJCC TNM staging system of breast cancer. The nomograph prognostic model was constructed and validated. Results The prediction performance of the new N-staging system for postoperative survival of M0 inflammatory breast cancer patients was better than the traditional N-staging system. The nomograph prognostic model showed an excellent clinical efficacy with a consistency index of 0.711. Conclusion The new N-staging system has good predictive performance for postoperative survival of M0 inflammatory breast cancer patients and can accurately reflect the prognosis.
Keywords Inflammatory breast neoplasms      Prognosis      Staging      SEER database     
ZTFLH:  R737.9  
Issue Date: 11 August 2022
 Cite this article:   
SUI Daxing,WANG Xueying,ZHANG Jiaxin. A New N-staging System for Predicting Postoperative Survival of M0 Stage Inflammatory Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 799-805.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.1532
http://www.zlfzyj.com/EN/Y2022/V49/I08/799
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
SUI Daxing
WANG Xueying
ZHANG Jiaxin
[1] Fouad TM, Kogawa T, Liu DD, et al. Overall survival differences
between patients with inflammatory and noninflammatory breast
cancer presenting with distant metastasis at diagnosis[J]. Breast
Cancer Res Treat, 2015, 152(2): 407-416.
[2] Devi GR, Hough H, Barrett N, et al. Perspectives on Inflammatory
Breast Cancer (IBC) Research, Clinical Management and
Community Engagement from the Duke IBC Consortium[J]. J
Cancer, 2019, 10(15): 3344-3351.
[3] Arias-Pulido H, Cimino-Mathews AM, Chaher N, et al. Differential
effects of CD20+ B cells and PD-L1+ immune cells on
pathologic complete response and outcome: comparison between
inflammatory breast cancer and locally advanced breast cancer
patients[J]. Breast Cancer Res Treat, 2021, 190(3): 477-489.
[4] Cserni G, Chmielik E, Cserni B, et al. The new TNM-based staging
of breast cancer[J]. Virchows Arch, 2018, 472(5): 697-703.
[5] Kinoshita T, Goto T. Links between Inflammation and Postoperative
Cancer Recurrence[J]. J Clin Med, 2021, 10(2): 228.
[6] Kida K, Hess KR, Lim B, et al. Validation of Prognostic Stage and
Anatomic Stage in the American Joint Committee on Cancer 8th
Edition for Inflammatory Breast Cancer[J]. Cancers (Basel), 2020,
12(11): 3105.
[7] Wang Z, Wang H, Ding X, et al. A large-cohort retrospective
study of metastatic patterns and prognostic outcomes between
inflammatory and non-inflammatory breast cancer[J]. Ther Adv
Med Oncol, 2020, 12: 1758835920932674.
[8] Liu C, Li H, Zhuo R, et al. Grade-lymph node ratio predicts
the survival of breast cancer in different molecular types: A
surveillance, epidemiology, and end results population-based
analysis[J]. Medicine (Baltimore), 2019, 98(28): e16436.
[9] Oven Ustaalioglu BB, Bilici A, Kefeli U, et al. Does the metastatic
lymph node ratio influence the disease-free survival of patients
with breast cancer: single-center experiences[J]. Oncology, 2010,
79(1-2): 105-111.
[10] Wecsler JS, Tereffe W, Pedersen RC, et al. Lymph node status in
inflammatory breast cancer[J]. Breast Cancer Res Treat, 2015,
151(1): 113-120.
[11] Rosso KJ, Tadros AB, Weiss A, et al. Improved Locoregional
Control in a Contemporary Cohort of Nonmetastatic Inflammatory
Breast Cancer Patients Undergoing Surgery[J]. Ann Surg Oncol,
2017, 24(10): 2981-2988.
[12] Mamouch F, Berrada N, Aoullay Z, et al. Inflammatory Breast
Cancer: A Literature Review[J]. World J Oncol, 2018, 9(5-6):
129-135.
[13] Adesoye T, Lucci A. Current Surgical Management of
Inflammatory Breast Cancer[J]. Ann Surg Oncol, 2021, 28(10):
5461-5467.
[14] Fouad TM, Barrera AMG, Reuben JM, et al. Inflammatory breast
cancer: a proposed conceptual shift in the UICC-AJCC TNM
staging system[J]. Lancet Oncol, 2017, 18(4): e228-e232.
[15] Schairer C, Hablas A, Eldein IAS, et al. Clinico-pathologic
and mammographic characteristics of inflammatory and noninflammatory
breast cancer at six centers in North Africa[J].
Breast Cancer Res Treat, 2019, 176(2): 407-417.
[16] Bertucci F, Rypens C, Finetti P, et al. NOTCH and DNA repair
pathways are more frequently targeted by genomic alterations in
inflammatory than in non-inflammatory breast cancers[J]. Mol
Oncol, 2020, 14(3): 504-519.
[17] Li J, Gonzalez-Angulo AM, Allen PK, et al. Triple-negative
subtype predicts poor overall survival and high locoregional
relapse in inflammatory breast cancer[J]. Oncologist, 2011,
16(12): 1675-1683.
[18] Rueth NM, Lin HY, Bedrosian I, et al. Underuse of trimodality
treatment affects survival for patients with inflammatory breast
cancer: an analysis of treatment and survival trends from the
National Cancer Database[J]. J Clin Oncol, 2014, 32(19):
2018-2024.
Related articles from Frontiers Journals
[1] LI Jinzhou, WANG Wenjie, YAO Yalong, MU Yanxi, CHEN Kang, SHEN Yimin, WANG Zhou, HUANG Zeping, CHEN Xiao. Development and Validation of Prognostic Nomogram Based on Negative Lymph Node Count for Patients with Gastric Signet Ring Cell Carcinoma#br#[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 923-930.
[2] HUANG Zhenghua, ZHOU Jian, LI Yufu, LIU Yanyan, ZHOU Keshu, SONG Yongping. Clinical Efficacy and Prognostic Factors of Autologous Hematopoietic Stem Cell Transplantation for Hodgkin’s Lymphoma in 38 Cases[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 952-955.
[3] XU XiaoFei, LI Yang, CHEN Lingyun, DAI Heyang, XUE Jiaojiao, LI Qingxia, . Research Progress of PNI and CONUT in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 961-964.
[4] JIA Lijuan, ZHANG Yunqiang, ZHANG Baihong, YUE Hongyun. Expression and Clinical Significance of m6A Methylatransferase ZC3H13 in Gastric Cancer Tissues and Serum[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 792-798.
[5] LI Jinzhou, HUANG Zeping, MU Yanxi, YAO Yalong, WANG Wenjie, LIU Haipeng, LIU Jie, WANG Zhou, CHEN Xiao. Prognostic Value of Negative Lymph Nodes Count in Solid Tumors[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 843-849.
[6] ZHOU Silei, SUN Guanqun, ZENG Tanlun, CHENG Zhuo, LIANG Xijun. Expression and Prognostic Value of CK2α' in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 662-666.
[7] XIA Lili, ZHU Xinyi, ZHANG Xiwei, LI Zhengjiang, LIU Shaoyan, LU Haizhen, AN Changming. Predictive Value of Depth of Invasion of Tongue Squamous Cell Carcinoma for Cervical Lymph Node Metastasis and Prognosis[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 675-681.
[8] ZHAN Jianghua, WANG Zhiru, . Progress and Comment on Surgical Treatment of Hepatoblastoma in Children[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 541-545.
[9] . Expression of MAD2L1 in Lung Adenocarcinoma and Its Effect on Immune Microenvironment[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 586-592.
[10] WANG Jue, JIN Zongrui, WANG Wei, YI Qilin, WANG Jilong, ZHU Hai, XU Banghao, GUO Ya, WEN Zhang. Prognostic Role of Immune-related Genes in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 599-605.
[11] LI Menghan, XIAO Qiong, GAO Peng, FU Yu, SUN Chenrui, SONG Yongxi. LncRNA Prognostic Risk Scoring Model for Gastrointestinal Tumors Based on TCGA Database[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 606-611.
[12] XU Shasha, HAN Xingmin. Research Advances on Application of 18F-FDG PET/CT in Clinical Diagnosis and Treatment of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 384-389.
[13] LEI Haike, LI Xiaosheng, LI Jieping, LIU Jun, XIAO Chunyan, WANG Ying, ZHANG Wei, LIU Yao, WU Yongzhong. Clinical Characteristics and Prognostic Influence Factors of Patients with AIDS-related Malignant Tumor[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 412-417.
[14] WU Fengyang, WU Qiuji, YANG Xiting, ZHONG Yahua. Clinical Features and Prognostic Factors of Adenoid Cystic Carcinoma of Head and Neck[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 427-431.
[15] ZHONG Zhenhua, FAN Fengfeng, JIANG Wenqiang, LI Zhanwen. Clinicopathological Characteristics and Prognosis of 35 Cases of Pregnancy-associated Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 432-437.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed